Pharmaceuticals : Shots - Health News Pharmaceuticals

Diseased brain tissue from an Alzheimer's patient showing amyloid plaques (in blue) located in the gray matter of the brain. Dr Cecil H Fox/Science Source/Getty Images hide caption

toggle caption
Dr Cecil H Fox/Science Source/Getty Images

Gilead Sciences' Harvoni can cure hepatitis C, but the drug costs a fortune. Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

The federal government spends more than $30 billion a year to fund the National Institutes of Health. What changes are in store under a new administration? NIH/Flickr hide caption

toggle caption
NIH/Flickr

Pfizer's Celebrex fared well in a safety study that compared the pain reliever with ibuprofen and naproxen. Daniel Acker/Bloomberg via Getty Images hide caption

toggle caption
Daniel Acker/Bloomberg via Getty Images

Safety Of Painkiller Celebrex Affirmed In New Study

  • Download
  • <iframe src="https://www.npr.org/player/embed/501033431/501975727" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Auvi-Q was pulled from the market in 2015 because of quality concerns. The drug's maker says the problems have been solved and that the product will be available in 2017. AP hide caption

toggle caption
AP

WFYI's Jake Harper reports health stories for Side Effects Public Media in Indianapolis. His newest health anxiety stems from the human papillomavirus, or HPV. Brian Paul/Side Effects Public Media hide caption

toggle caption
Brian Paul/Side Effects Public Media

Is 20-Something Too Late For A Guy To Get The HPV Vaccine?

  • Download
  • <iframe src="https://www.npr.org/player/embed/497677367/498219569" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A job reviewing drug applications at the Food and Drug Administration can be the springboard for a career in industry. Andrew Harnik/AP hide caption

toggle caption
Andrew Harnik/AP

Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. Boston Globe via Getty Images hide caption

toggle caption
Boston Globe via Getty Images

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

  • Download
  • <iframe src="https://www.npr.org/player/embed/495174472/495295191" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Where are the generic alternatives to EpiPen and other expensive drugs that have lost patent protection? Victor J. Blue/Bloomberg via Getty Images hide caption

toggle caption
Victor J. Blue/Bloomberg via Getty Images